After CPhI China, En-cphi.cn interviewed Mr. Jaume Reguant, director of the Bioiberica Health Care Business Unit.
The main business of Bioiberica is Heparin. Meanwhile, as a world reference and an international leader in joint health and mobility compounds, Bioiberica is the first European producer of Chondroitin Sulfate.
CPhI : What are the latest products and technologies you have brought to CPHI China 2018? What did you gain form 2018CPHI China and how do you think of CPHI China 2018? How do you think of the Chinese market for your business?
Mr. Jaume Reguant: At CPhI China 2018 we presented our top branded ingredients. b-2Cool®, a native type II collagen-based natural ingredient that helps maintain joint health thanks to its immune-mediated mechanism of action. Mobilee®, a patented ingredient rich in hyaluronic acid, polysaccharides and collagen, which contributes to maintain joint function and muscle strength. And also our pharma quality Glucosamine, a maximum purity and quality product which has proved to reduce joint pain and to improve mobility.
China is the world’s second largest pharma economy and it has a huge market potential. As expected, CPhl China has become the most important pharmaceutical trade show on active ingredients in the Asia-Pacific region and it is a good opportunity to meet our distributors and to search for new partners.
Bioiberica can bring experience, quality and science to the Chinese market. Experience of more than 40 years in the identification and extraction of biomolecules of high biological and therapeutic value, from tissues of animal origin, which are transformed into high quality active pharmaceutical and nutraceutical ingredients and products. Quality thanks to our productive model: Bioiberica is vertically integrated, being present throughout the whole life of the product, from development through production to marketing and our processes are especially designed to minimize any possibility of biological risk. And Science because our products are supported by more than 150 publications.
CPhI: What effective quality control measures have been implemented to ensure the quality of your products from the slaughterhouse to the pharmaceutical active ingredient?
Mr. Jaume Reguant: Raw materials are selected and controlled in origin at the eight plants of the company in Spain, Germany, the United States, Brazil, Italy and Poland. This provides a strong supply chain model, as well as production capacity and flexibility. All these plants have implemented a common quality system and environmentally safe processes.
The final purification process, in which the product is converted into a pharmaceutical ingredient, takes place at our state-of-the-art facility in Palafolls (Barcelona). The result is a premium quality and safe product adapted to our client requirements.
CPhI: Could you share more about your leadership in heparin, pharmaceutical specialities and active ingredients for joint health, plant stress and immunological and digestive health? Especially, for Heparin, any progress about new applications related with anti-tumoral, anti-inflammatory and antiviral activity study? Any progress by studying the effect of heparin in the treatment of cancer, chronic obstructive pulmonary disease (COPD), organ transplants, malaria and asthma?
Mr. Jaume Reguant: Since our foundation in 1975, we have been focused on the production of Heparin. We are very well aware that it is an active ingredient indispensable for human health and that it is essential to be able to offer the maximum guarantees of safety and traceability. Today, we are the leading Heparin API manufacturer and one out ...
(All Rights Reserved)